BTTX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 15:50):

Stats
Today's Volume	547 883
Average Volume	5.91M
Market Cap	490 640
EPS	$0 ( 2024-04-04 )
Next earnings date	( $-0.120 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0100
ATR14	$0.00100 (11.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-09	Perry David P	Buy	839 895	Common Stock
2024-01-09	Perry David P	Buy	1 471 453	Common Stock
2023-12-18	Perry David P	Buy	3 750	Common Stock
2023-12-18	Carmona Richard H	Buy	3 750	Common Stock
2023-12-18	Lavizzo-mourey Risa J	Buy	3 750	Common Stock

INSIDER POWER
99.11
Last 98 transactions
Buy: 15 006 415 \| Sell: 72 086

Better Therapeutics, Inc. Correlation

10 Most Positive Correlations
FRBK	0.881
EBC	0.87
GSMG	0.869
CSGP	0.857
CBNK	0.855
ADTN	0.852
AADI	0.852
CMLS	0.85
DISH	0.849
ACRS	0.846

10 Most Negative Correlations
TMKR	-0.88
VRCA	-0.878
BIOT	-0.87
KSICU	-0.866
SVSVU	-0.865
HYAC	-0.858
MSSA	-0.853
RNLX	-0.85
MHUA	-0.85
NSIT	-0.847

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Better Therapeutics, Inc. Financials

Annual	2022
Revenue:	$0
Gross Profit:	$-2.73M (0.00 %)
EPS:	$-1.690

Q3	2023
Revenue:	$0
Gross Profit:	$-841 000 (0.00 %)
EPS:	$-0.150

Q2	2023
Revenue:	$0
Gross Profit:	$-797 000 (0.00 %)
EPS:	$-0.240

Q1	2023
Revenue:	$0
Gross Profit:	$-755 000 (0.00 %)
EPS:	$-0.390

Financial Reports:

No articles found.

Better Therapeutics, Inc.

Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.